Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investor Eye: Octopus Ventures Tackles Tough, Taboo Problems In Health Care

Executive Summary

In an interview with Medtech Insight, Octopus Ventures partner Pooja Sikka explained the approach Octopus takes to investments, and the key challenges the fund wants to address.

You may also be interested in...



Investor Eye: Novalis Embraces Early Investment And Enabling Technology

Novalis Biotech employs early targeted investments to produce returns, focusing on enabling technologies and risky ventures in diagnostics and digital health.

Pandemic Perspectives: A Lasting Impact On Medtech, But Not Dealmaking

The COVID-19 pandemic has fundamentally changed health care and the life sciences, KPMG analyst Kristin Pothier concludes in a new report on the medtech investment outlook.

Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics

Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.

Topics

UsernamePublicRestriction

Register

MT143682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel